title: High-dose-rate brachytherapy in the treatment of carcinoma of the prostate.
abstract: BACKGROUND
  Although radical prostatectomy for localized disease is considered as a standard of care, external-beam radiotherapy and brachytherapy are equally effective. We report on the technique and preliminary results of high-dose-rate (HDR) brachytherapy using a temporary iridium-192 implant technique.
  
  
  METHODS
  The authors reviewed the literature on the techniques, treatment protocols, and results of HDR brachytherapy in the treatment of carcinoma of the prostate, and they report their own protocols, technique, and results.
  
  
  RESULTS
  The combination of HDR brachytherapy and external irradiation has been well tolerated by all 200 patients in our series, with less than 3% grade 3 late complications and with 95% PSA relapse-free survival with a median follow-up of 24 months.
  
  
  CONCLUSIONS
  HDR brachytherapy may be the most conformal type of irradiation in the treatment of carcinoma of the prostate regardless of tumor size, anatomical distortion, and organ mobility.
authors.affiliation: Department of Radiation Oncology, Long Beach Memorial Medical Center, 2801 Atlantic Avenue, Long Beach, CA 90806-1737, USA. VSharples@memorialcare.org
authors.forename: A M
authors.initials: AM
authors.lastname: Syed
authors.forename: A
authors.initials: A
authors.lastname: Puthawala
authors.forename: A
authors.initials: A
authors.lastname: Sharma
authors.forename: S
authors.initials: S
authors.lastname: Gamie
authors.forename: A
authors.initials: A
authors.lastname: Londrc
authors.forename: J M
authors.initials: JM
authors.lastname: Cherlow
authors.forename: S J
authors.initials: SJ
authors.lastname: Damore
authors.forename: N
authors.initials: N
authors.lastname: Nazmy
authors.forename: K M
authors.initials: KM
authors.lastname: Sheikh
authors.forename: S J
authors.initials: SJ
authors.lastname: Ko
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D018572:Disease-Free Survival; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D007496:Iridium Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007496:Iridium Radioisotopes; D017430:Prostate-Specific Antigen